Newsstand | Page 12 | Aplastic Anemia & MDS International Foundation


Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Firstline Eltrombopag Receives Breakthrough Designation for Severe Aplastic Anemia

Originally Published: 03/01/2018
The FDA granted breakthrough-therapy designation for firstline eltrombopag to treat severe aplastic anemia (SAA).

MDS Update - January 2018

Originally Published: 02/26/2018

Scientists Discover a Bone-Deep Risk for Heart Disease

Originally Published: 02/01/2018
Few doctors, and even fewer patients, have heard of CHIP. But it is emerging as a major cause of heart attacks and stroke, as deadly as high blood pressure or cholesterol. Full article here.

TARGET Study Finds Major Differences between Childhood and Adult AML

Originally Published: 01/30/2018
An NCI-funded study has found that, at the genetic level, acute myeloid leukemia (AML) differs greatly between younger and older patients.

Therapeutic Vaccine Combination May Help Patients with Myelodysplastic Syndrome

Originally Published: 01/30/2018
It may be possible to vaccinate against induced NY-ESO-1 expression to produce an antigen-specific immune response in patients with high-risk myelodysplastic syndrome (MDS), according to a study by researchers at Roswell Park Comprehensive Cancer Center. They have found a new immunotherapy approach that may significantly benefit high-risk MDS patients who have limited options.

Monitoring For AML Remissions: Are We Measuring Properly?

Originally Published: 01/18/2018
When it comes to monitoring patients previously treated for acute myeloid leukemia (AML), determining who is in remission is still an imperfect process, according to Richard M. Stone, M.D. Full article here.

AAMDSIF Letter Supporting HR 4215, The Patient Access to Cellular Transplant Act

Originally Published: 01/11/2018
CEO Kathleen Weis expresses full support by AAMDSIF for HR 4215, the The Patient Access to Cellular Transplant (PACT) Act. HR4215 provides that Medicare would remiburse stem cell, bone marrow, and cord blood transplants at the same rate as other transplants.    

FDA Okays Complete Blood Cell Count Test

Originally Published: 01/01/2018
The U.S. Food and Drug Administration (FDA) cleared the XW-100 Automated Hematology Analyzer, a complete blood cell count (CBC) test that can be used in more health-care settings – including physicians’ offices and clinics – and by a wider range of support staff than available testing methods. The test also delivers faster results.  Full article here.

Post-BMT study of pediatric patients

Originally Published: 12/27/2017
Abstract BACKGROUND AND OBJECTIVE: Timely antibiotic administration in immunocompromised patients is associated with improved outcomes. The aim of our study was to decrease the mean time to administration of antibiotics in hospitalized bone marrow transplant patients with fever from 75 to <60 minutes. METHODS: By using the Model of Improvement, we performed plan-do-study-act cycles to design, test, and implement high-reliability interventions to decrease time to antibiotics. Nursing, physician, and pharmacy interventions were successfully applied to improve timely antibiotic...

Summary for Patients from ASH 2017

Originally Published: 12/21/2017
Summary for Patients from ASH 2017